Janssen Biotech Inc.

The South Korea government plans to improve the transparency and objectivity of standards for pharma firms to officially qualify as “innovative” and eligible for special policy treatment, amid foreign

Leading South Korean antibody-drug conjugate (ADC) specialist LigaChem Biosciences has made a $25m investment for an initial 26.6% equity stake in existing partner IKSUDA Therapeutics, and secured the

Najat Khan has built her career at the intersection of drug development and technological innovation. As chief R&D and commercial officer at Recursion, she is helping to scale one of biotech’s (or

The US Food and Drug Administration’s high biosimilar approval standards appear to have streamlined its ability to deem all of the products interchangeable, should Congress enact the necessary legisla